Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Cardiovascular disease risk is significantly higher in patients with chronic inflammatory conditions like rheumatoid arthritis (RA).
• Atherosclerosis shares pathophysiological similarities with autoimmune diseases, prompting a re-evaluation of cardiovascular risk in RA.
• The management of RA is evolving with targeted biological agents, necessitating a deeper understanding of associated vascular complications.

Purpose of the Study:

• To review the causes of increased vascular disease in rheumatoid arthritis.
• To explore the role of the receptor for advanced glycation end products (RAGE) in cardiovascular disease and RA.
• To discuss the potential impact of RAGE functional polymorphisms, specifically the Glycine 82 Serine variant, on disease expression.

Main Methods:

• Literature review focusing on cardiovascular risk factors in RA.
• Examination of pathophysiological mechanisms linking inflammation and vascular disease.
• Analysis of the role of RAGE and its polymorphisms in RA and cardiovascular outcomes.

Main Results:

• Chronic inflammation in RA contributes to increased cardiovascular disease risk.
• RAGE is implicated as a molecule influencing inflammation and autoimmunity, with a potential role in RA-associated vascular disease.
• Functional polymorphisms in RAGE, such as Glycine 82 Serine, may modulate disease expression.

Conclusions:

• Understanding the mechanisms linking RA and cardiovascular disease is crucial for improved patient management.
• RAGE and its genetic variants represent potential therapeutic targets or biomarkers for cardiovascular risk in RA patients.
• Further research into RAGE's role could lead to novel strategies for preventing and treating vascular complications in rheumatoid arthritis.